GLP-1

Yale University researchers easily obtained GLP-1 prescriptions online using fake patient profiles, with some prescriptions issued in under five minutes and minimal clinician interaction. A study published in JAMA medical journal details how researchers tested 49 websites to secure these prescriptions.

Medicare has initiated a GLP-1 pilot program. The article highlights that Medicare coverage of these weight loss drugs could benefit millions of people.

A Harvard University working paper found that women taking GLP-1 weight loss medications were 27 percentage points more likely to find a job if they were unemployed before treatment. The study also linked the drugs to improved dating prospects for women.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50, making these previously expensive treatments more affordable for many older Americans.

The article discusses Medicare's GLP-1 Bridge program, which provides coverage for GLP-1 receptor agonists to manage diabetes and obesity. It aims to address gaps in access to these medications for eligible beneficiaries.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.

Peptides are widely promoted in health and beauty for benefits like weight loss and tissue repair, but many sold as 'research only' lack FDA approval. The FDA is easing access to peptides despite warnings about undermining drug approval, while experts note that only rigorously studied, FDA-approved peptides (like Tirzepatide and Semaglutide) have strong scientific backing.

Jenny Mollen reported severe side effects, including 'blood everywhere,' from microdosing Tirzepatide, a GLP-1 weight loss drug, while taking a cocktail of peptides.

A man was granted compassionate-use access to an experimental GLP-1 drug developed by Eli Lilly. The exclusive report details the sole individual given special access to the obesity treatment, as covered in STAT's health policy newsletter.

UPS is investing $48 million to build 27 temperature-controlled facilities across three continents to meet the rising demand for refrigerated pharmaceuticals driven by the GLP-1 drug boom. The expansion reflects growing logistical challenges for shipping refrigerated medications.

The new GLP-1 generation includes daily tablets and 'blockbuster fat jabs' for obesity treatment set to arrive in the UK, with claims of being more affordable than Mounjaro.

Glanbia, a protein-powder maker, is experiencing a share price increase driven by the GLP-1 craze. The company's stock is rallying as the trend gains popularity.

Accidental GLP-1 medication overdoses have increased significantly, with a nearly 1,500% rise in poison control calls since 2019. Errors often stem from measurement confusion, compounded medications, and inadequate patient education rather than intentional misuse, according to experts like Dr. Ivania Rizo and Dr. Leslie Golden.

Actress Mayim Bialik described her negative experience with a GLP-1 medication as a 'nightmare.' Research indicates 44% of GLP-1 users reported at least one side effect.

Actress Mayim Bialik described her experience with a GLP-1 as a 'nightmare.' Research found 44% of GLP-1 users reported at least one side effect.

Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.

A new triple-action weekly jab for type 2 diabetes, retatrutide, showed significant reductions in blood sugar and body weight in phase 3 trials. Patients receiving retatrutide lost over four times more weight and experienced more than twice the drop in HbA1c compared to placebo. The drug mimics three gut hormones (GLP-1, GIP, and glucagon) and differs from existing diabetes medications by engaging the glucagon receptor to increase energy expenditure.

New experimental weight-loss drugs are being developed to improve upon existing GLP-1 therapies like Zepbound and Wegovy. These therapies aim to offer better alternatives for patients experiencing nausea or daily pill regimens.

A monthly GLP-1 drug could reduce the number of injections patients take annually from 52 to 12. This development aims to improve convenience for weight loss drug users.

Serena Williams announced her return to tennis at age 44 for a doubles match in London, crediting GLP-1 peptides for weight loss and improved mobility. Her comeback highlights growing interest in peptides among athletes and health enthusiasts for performance and longevity benefits.

The article discusses the Withings BodyFit smart scale, marketed as 'built for GLP-1 users,' which was showcased at a midtown gym event attended by fitness influencers and tech reporters. The piece is part of The Verge's Optimizer newsletter, written by senior reviewer Victoria Song, focusing on health and tech products.

Bernstein has become pessimistic about packaged food stocks, citing inflation and GLP-1 as key challenges. The article references Campbell's Soup cans in a Florida store as an example.

New medical information suggests that GLP-1 medications may help reduce the risk of developing breast cancer. WGN's Dina Bair reported on this development on June 2.

Withings has launched a more affordable mid-range BodyFit scale aimed at GLP-1 users who require closer monitoring of their muscle mass.

A GLP-1 user reported experiencing a bizarre hearing side effect, describing it as sounding like 'Darth Vader.' The article highlights unusual auditory impacts linked to weight loss drugs.

The article discusses the shift from pill-based to injection-based treatments in the U.S., highlighting the rise of GLP-1 drugs like Ozempic and Mounjaro for weight loss, increased use of Botox and IVF-related hormone injections, and the growth of 'needle-forward' wellness services. It notes the FDA approval of semaglutide in 2021 as a catalyst for the obesity medication trend, alongside cultural influences like Joe Rogan's promotion of peptides.

New NIH research reveals that semaglutide triggers varied responses in appetite-controlling brain cells, explaining why GLP-1 weight-loss drugs like Ozempic and Wegovy lose effectiveness over time. Scientists also identified a potential method to prolong the drugs' efficacy, helping patients overcome weight-loss plateaus.

A controversial liquid used by biohackers may help promote hair growth and prevent hair thinning caused by GLP-1 medications. The article discusses potential benefits of this substance for addressing baldness and GLP-1 drug side effects.

Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.

Eli Lilly's new weight loss drug retatrutide has shown remarkable trial results, potentially outperforming existing GLP-1 medications. The drug works by mimicking three hormones that regulate hunger and fat burning. NBC medical contributor Dr. Natalie Azar discusses the trial outcomes and FDA approval timeline.

The peptide market is experiencing rapid growth as GLP-1 weight-loss medications gain popularity, with largely unregulated peptides being sold through compounding pharmacies and unverified vendors. The FDA is evaluating whether to loosen regulations on several peptides, while compounding pharmacies have expanded to meet demand and offer dosing flexibility that commercial products cannot provide.

A new obesity treatment called retatrutide may help preserve muscle during weight loss by activating three hormones involved in regulating blood sugar, appetite and metabolism. Retatrutide is a triple agonist that has shown promising results in clinical trials with a lower side effect profile. It is administered as a once-weekly subcutaneous injection and can help people lose up to a third of their body weight.

GLP-1 users are turning to telehealth services to access weight loss drugs, providing a convenient and accessible way to manage their weight. This shift towards telehealth highlights the growing demand for remote healthcare solutions. The trend is expected to continue as more people seek online health services.

Research reveals that some individuals, referred to as 'super-responders', experience significant weight loss when taking GLP-1 drugs like Wegovy, while others do not respond at all. This variation in response is a key finding in emerging research on GLP-1 medications. The difference in response rates among patients may lead to more personalized treatment approaches.

The first human GLP-1 gene therapy trial has received approval. Dr. Harith Rajagopalan commented on the potential of GLP-1 medicines in treating obesity and Type 2 diabetes. This development may lead to new treatments for these conditions.

J.P. Morgan upgraded Cheesecake Factory's stock due to the restaurant chain's ability to feed everyone, including GLP-1 users. This upgrade comes as the restaurant industry faces anxiety from weight-loss drugs and cautious consumers. The upgrade suggests Cheesecake Factory has found a way to thrive in challenging market conditions.

Hims takes a $33 million hit from GLP-1 'pivot'. The news is part of STAT's Health Tech newsletter, which covers technology in life sciences. The newsletter also mentions a series on the public health crisis around alcohol.

Biocon is pushing for generic GLP-1, a significant development in India's pharmaceutical industry. The company's efforts aim to make this medication more accessible. Biocon's initiative has the potential to impact the Indian healthcare sector.

Researchers have created a new obesity drug that uses GLP-1/GIP signals to target cells and enhance metabolism, outperforming existing treatments in mice by curbing appetite and improving blood sugar levels. The drug can be used at lower doses, potentially reducing side effects. It shows promise for effective weight loss.